Alcami Capacity Update October 2025: Small Molecule

Development trends in oral solid dose manufacturing have leaned heavily towards stabilizing and enhancing performance of new molecules up front enabling fast and efficient bench to clinic workflows and refined Quality Target Product Profiles (QTPPs). Additionally, onshoring of late phase and commercial programs has accelerated, driven by a heightened demand for high quality pharmaceutical products and need for greater supply chain security highlighting the value of flexible manufacturing partnerships prior to commercialization.